Introduction and Objectives: Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the USA, and a major cause of medication discontinuation. However, DILI is often under-diagnosed, primarily due to the lack of agreed upon diagnostic criteria and limiting coding nomenclature.
Materials and methods: We conducted a retrospective observational analysis of demographic, clinical, and laboratory data for 55 patients hospitalized in an Israeli tertiary care medical center between 2005-2017 and diagnosed with DILI.
Results: We identified 55 patients hospitalized with DILI over 12 years. DILI was associated with female gender and older age. Hepatocellular injury was the most common type of liver injury (49.0%). Common manifestations included fever (41.8%), weakness (41.8%) and jaundice (34.5%). The major offending drug group was antibiotics (35.0%) with amoxicillin and clavulanate being the most common drugs (7.2%). Most cases were caused by drugs administered orally (84%), while cholestatic injury was associated with intravenous administration. De Ritis ratio (AST/ALT) was above 1.0 in 75% of cases.
Conclusions: Most DILI was caused by oral antibiotics. The incidence of DILI in our study was low, possibly due to under-diagnosis or misclassification. The adoption of the updated international classification of disease 10th edition may improve reporting rates. Utilization of the De Ritis ratio may help to differentiate between DILI and viral hepatitis.
Keywords:
Published on: Jun 1, 2021 Pages: 36-40
Full Text PDF
Full Text HTML
DOI: 10.17352/2455-2283.000095
CrossMark
Publons
Harvard Library HOLLIS
Search IT
Semantic Scholar
Get Citation
Base Search
Scilit
OAI-PMH
ResearchGate
Academic Microsoft
GrowKudos
Universite de Paris
UW Libraries
SJSU King Library
SJSU King Library
NUS Library
McGill
DET KGL BIBLiOTEK
JCU Discovery
Universidad De Lima
WorldCat
VU on WorldCat
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."